Overview
The purpose of the study is to evaluate the presence of early vascular aging 6 months and 12 months after COVID-19 infection.
Description
After being informed about the study and potential risks, all eligible patients giving written informed consent will undergo a comprehensive non-invasive assessment of vascular and cardiac function 6 months and 12 months after COVID-19 infection. Cardiovascular events and mortality will be collected 2, 5 and 10 years after inclusion
Eligibility
Inclusion Criteria:
- age >18 years, both sexes;
- written informed consent;
- affiliation to a social security regime;
- a recent diagnosis of COVID19 (6±3 months) proven by PCR or serology (for group 1,2,3)
- hospitalization in intensive care unit for COVID19 (for group 1)
- hospitalization in a medicine unit for COVID19 (for group 2)
- no hospitalization for COVID19 or hospitalization less than 24h (for group 3)
- a negative test for SARS-nCOV2 infection (PCR or serology)(for group 4)
Exclusion Criteria:
- Age <18 years
- Inability to express consent of the study
- Diseases carrying out a life -expectancy <1 year according to clinical judgment
- Pregnancy and breastfeeding
- Foreseen inability to attend scheduled visits